Gencurix Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Sep 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Data processing, analysis method of gene expression data to identify endogenous reference genes (US 10,304,561) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Apr 1, 2027The maintenance fee for Gene for predicting the prognosis for early-stage breast cancer, and a method for predicting the prognosis for early-stage breast cancer by using the same (US 10,428,386) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
- 1 fee due Jun 12, 2027The maintenance fee for Method for predicting prognosis of breast cancer patient (US 11,840,733) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Method for determining nucleic acid quality of biological sample (US 11,970,732) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,304,561 | Data processing, analysis method of gene expression data to identify endogenous reference genes In force · From the USPTO record | In force | From the USPTO record | |
| US 9,639,660 | Data Processing, Analysis Method of Gene Expression Data to Identify Endogenous Reference Genes In force · Medium confidence | In force | Medium confidence | |
| US 10,428,386 | Gene for predicting the prognosis for early-stage breast cancer, and a method for predicting the prognosis for early-stage breast cancer by using the same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,655,187 | Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,718,030 | Methods for predicting effectiveness of chemotherapy for a breast cancer patient In force · From the USPTO record | In force | From the USPTO record | |
| US 11,261,482 | Composition for detecting epidermal cell growth factor receptor gene mutation, and kit comprising same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,970,732 | Method for determining nucleic acid quality of biological sample In force · From the USPTO record | In force | From the USPTO record | |
| US 11,220,716 | Methods for predicting the prognosis of breast cancer patient In force · From the USPTO record | In force | From the USPTO record | |
| US 11,840,733 | Method for predicting prognosis of breast cancer patient In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 9: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 3 no status recorded